H&T Presspart and Cohero Health have launched market-ready, intuitive, fully-embedded and connected metered dose inhaler (eMDI) aimed at boosting adherence and enabling continually optimised care of patients with asthma and COPD.

It is claimed to be the only eMDI integrated seamlessly with BreatheSmart from Cohero Health, a thorough respiratory disease management platform that allows tracking of both controller and rescue medications, along with clinically right lung function measurement in real-time.

It is essential to use preventer (controller) inhalers is essential to boost quality of life, control symptoms and prevent attacks, which are responsible for 3.25 million deaths globally every year.

“Fewer than 50% of patients take their preventer medication as prescribed, which leads to poor symptom management, hospitalisations, avoidable deaths and spiraling healthcare costs.”

Fewer than 50% of patients take their preventer medication as prescribed, which leads to poor symptom management, hospitalisations, avoidable deaths and spiraling healthcare costs.

H&T Presspart eMDI is the result of a multi-year development between H&T Presspart, a leading manufacturer of MDI devices, and Cohero Health, a digital health company.

H&T Presspart CEO Peter Schmelzer said: “In designing the eMDI, our mission was to help pharmaceutical companies bring the best possible care to patients in an intuitive device in the fastest time and most cost-efficient way.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Cohero Health co-founder and CEO Mellissa Manice said: “We have thus combined the design of the world’s most widely used and established inhaler technology with the only respiratory platform that gives a complete and objective picture of how a patient is responding to treatment between reviews.”

The eMDI, by tracking, recording and sharing data on the use of both preventer (controller) and reliever (rescue) medications,  will engage and empower patients in their self-care, thereby leading to improved adherence, whilst allowing real-time monitoring of medication use and symptom flare-ups by caregivers and the healthcare community.

eMDI’s medication utilisation data can be merged in real-time with lung function data from Cohero Health’s mSpirometer, which is  a clinical grade handheld wireless spirometer that appropriately measures critical lung function metrics. This enables tracking and analysing of the effects of preventer and rescue medication use on lung function.

Sensors embedded within the inhaler track the date and time of medication use as well as the quality of delivery, which is both recorded in onboard memory and shared wirelessly bluetooth, syncing seamlessly with the BreatheSmart app, which can offer  customised reminders, real-time alerts and updates on medication usage, as well as weekly and monthly summary reports.